Overview

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Trastuzumab
Vinblastine
Vinorelbine